Skip to main content
. 2017 Feb 18;9(5):242–251. doi: 10.4254/wjh.v9.i5.242

Table 2.

Summary of studies each of which included ≥ 100 patients who underwent hepatectomy for non-colorectal non-neuroendocrine liver metastases (disease-free survival)

Ref. Year No. of patients MDFST (mo) 3-ydfsr (%) 5-ydfsr (%) Factors associated with worse disease-free survival
Elias et al[7] 1998 1201 NR NR 282 NR
Yedibela et al[9] 2005 1501 NR NR NR NR
Weitz et al[8] 2005 141 17 30 NR Primary tumor, diseas-free interval ≤ 24 mo
Adam et al[10] 2006 1452 13 27 21 NR
Lendoire et al[11] 2007 106 NR NR NR NR
O'Rourke et al[12] 2008 102 18 37 27 Diameter of liver metastasis > 5 cm, extrahepatic nodal disease
Groeschl et al[13] 2012 420 NR NR NR NR
Takemura et al[14] 2013 145 10 21 18 Blood transfusuion, preoperative chemotherapy
Hoffmann et al[15] 2015 150 21 36 29 NR
Schiergens et al[16] 2016 167 15 NR NR > 3 liver metastases, extrahepatic disease, residual tumor (R1,2)
1

Patients with neuroendocrine tumors were excluded;

2

Results including neuroendocrine tumors. MDFST: Median disease-free survival time; ydfsr: Year disease-free survival ratio; NR: Not reported.